222. Primary nephrotic syndrome Clinical trials / Disease details


Clinical trials : 285 Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-004174-64-DK
(EUCTR)
08/03/202216/12/2021Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosisA pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) - ACTION3 Focal segmental glomerulosclerosis
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 21.1;Level: LLT;Classification code 10016832;Term: Focal & segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Repagermanium
Product Code: DMX-200
INN or Proposed INN: Repagermanium
Dimerix Bioscience Pty LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
286Phase 3France;United States;Taiwan;Hong Kong;Argentina;Spain;Brazil;Australia;Denmark;United Kingdom;New Zealand;Korea, Republic of